These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 620496)

  • 21. Detection of renovascular hypertension with angiotensin II blockade.
    Baer L; Parra-Carrilo JZ; Radichevich I; Williams GS
    Ann Intern Med; 1977 Mar; 86(3):257-60. PubMed ID: 842983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].
    Beyer J; Liebau G; Steiner B; Hayduk K
    Klin Wochenschr; 1978 Sep; 56(17):859-64. PubMed ID: 713415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of 12-hour infusions of saralasin or captopril on blood pressure in hypertensive conscious rats. Relationship to plasma renin, duration of hypertension, and effect of unclipping.
    Bing RF; Russell GI; Swales JD; Thurston H
    J Lab Clin Med; 1981 Aug; 98(2):302-10. PubMed ID: 7019368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of the angiotensin II antagonist saralasin on plasma aldosterone concentration and on blood pressure before and during sodium depletion in normal subjects.
    Agabiti-Rosei E; Brown JJ; Brown WC; Fraser R; Trust PM; Lever AF; Morton JJ; Robertson JI
    Clin Endocrinol (Oxf); 1979 Mar; 10(3):227-34. PubMed ID: 455738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis.
    Schroeder ET; Anderson GH; Goldman SH; Streeten DH
    Kidney Int; 1976 Jun; 9(6):511-9. PubMed ID: 940284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II and not sodium status is the major determinant of the agonistic/antagonistic balance of saralasin's actions.
    Fagard R; Amery A; Lijnen P
    Clin Sci (Lond); 1980 Dec; 59 Suppl 6():75s-78s. PubMed ID: 7004740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma catecholamines and the pressor response to Sar1-Ala8-angiotensin II in man.
    McGrath BP; Ledingham JG; Benedict CR
    Clin Sci Mol Med; 1977 Oct; 53(4):341-8. PubMed ID: 913058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glomerular hemodynamics in rats with chronic sodium depletion. Effect of saralasin.
    Steiner RW; Tucker BJ; Blantz RC
    J Clin Invest; 1979 Aug; 64(2):503-12. PubMed ID: 457865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reactive hyperreninemia in renovascular hypertension after angiotensin blockage with saralasin or converting enzyme inhibitor.
    Case DB; Laragh JH
    Ann Intern Med; 1979 Aug; 91(2):153-60. PubMed ID: 464461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of 1-sar-8-ala-angiotensin II on arterial pressure, renin and aldosterone in hypertension.
    Fagard R; Lijnen P; Amery A; Reybrouck T
    Contrib Nephrol; 1978; 11():175-8. PubMed ID: 699588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between the hypotensive and renin-stimulating actions of diuretic therapy in hypertensive patients.
    Leonetti G; Terzoli L; Sala C; Bianchini C; Sernesi L; Zanchetti A
    Clin Sci Mol Med Suppl; 1978 Dec; 4():307s-309s. PubMed ID: 282074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin.
    Case DB; Wallace JM; Keim HJ; Weber MA; Drayer JI; White RP; Sealey JE; Laragh JH
    Am J Med; 1976 Nov; 61(5):790-6. PubMed ID: 185903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients.
    Case DB; Wallace JM; Keim HJ; Sealey JE; Laragh JH
    Am J Med; 1976 May; 60(6):825-36. PubMed ID: 1020762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of saralasin on normal blood pressure and on reno-vascular hypertension (author's transl)].
    Beckerhoff R; Vetter W; Furrer J; Nussberger J; Schmied U; Siegenthaler W
    Dtsch Med Wochenschr; 1976 Mar; 101(11):398-401. PubMed ID: 1253700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin II blockade during combined thiazide-beta-blocker treatment.
    Ibsen H; Leth A; McNair A; Christensen NJ; Giese J
    Scand J Clin Lab Invest; 1980 Jun; 40(4):325-31. PubMed ID: 6106282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Renovascular hypertension: prediction of surgical treatment by angiotensin II blockade and saralasin (author's transl)].
    Mimran A; Deschodt G; Barjon P; Mary H; Thevenet A
    Nouv Presse Med; 1978 Dec; 7(43):3889-93. PubMed ID: 733540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin blockade in renovascular hypertension: a controlled, prospective study.
    Marks LS; Maxwell MH; Gross C; Waks U; Kaufman JJ
    Br J Urol; 1977 Jun; 49(3):181-8. PubMed ID: 334316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Saralasin for renovascular or essential hypertension (author's transl)].
    Arlart I; Rosenthal J
    Dtsch Med Wochenschr; 1978 Nov; 103(45):1790-6. PubMed ID: 710289
    [No Abstract]   [Full Text] [Related]  

  • 40. Renin dependency of blood-pressure. Analysis by angiotensin II antagonist P113 in hypertensive patients treated with salt depletion and propranolol.
    Geyskes GG; Boer P; Vos J; Dorhout Mees EJ
    Lancet; 1976 May; 1(7968):1049-51. PubMed ID: 57453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.